Market capitalization | $1.69m |
Enterprise Value | $-830.00k |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.19 |
EV/Sales (TTM) EV/Sales | -0.12 |
P/S ratio (TTM) P/S ratio | 0.24 |
P/B ratio (TTM) P/B ratio | 0.25 |
Revenue growth (TTM) Revenue growth | -13.91% |
Revenue (TTM) Revenue | $7.18m |
As a Free StocksGuide user, you can view scores for all 6,842 stocks worldwide.
1 Analyst has issued a forecast ReShape Lifesciences, Inc.:
1 Analyst has issued a forecast ReShape Lifesciences, Inc.:
Mar '25 |
+/-
%
|
||
Revenue | 7.18 7.18 |
14%
14%
|
|
Gross Profit | 4.57 4.57 |
17%
17%
|
|
EBITDA | -6.28 -6.28 |
47%
47%
|
EBIT (Operating Income) EBIT | -6.30 -6.30 |
47%
47%
|
Net Profit | -3.46 -3.46 |
68%
68%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
ReShape Lifesciences Inc. operates as a medical device company, which focuses on technology to treat obesity and metabolic diseases. It operates through the following segments: Lap-Band, ReShape Vest and ReShape vBloc. The company was founded on December 2002 and is headquartered in San Clemente, CA.
Head office | United States |
CEO | Paul Hickey |
Employees | 29 |
Founded | 2002 |
Website | www.reshapelifesciences.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.